Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PRecision Oncology Evidence Development in Cancer Treatment - Liquid AKA the Real World Clinical Utility of ctDNA Analysis for Decision Making and Access to Precision Therapy for Advanced Cancer Patients in BC: The RAPTor Sub-study

NCT05057234 is registered in ClinicalTrials.gov with British Columbia Cancer Agency as lead sponsor.

NCT NCT05057234
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05057234 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PRecision Oncology Evidence Development in Cancer Treatment - Liquid AKA the Real World Clinical Utility of ctDNA Analysis for Decision Making and Access to Precision Therapy for Advanced Cancer Patients in BC: The RAPTor Sub-study
Lead sponsor
British Columbia Cancer Agency
Phase
Not applicable
Overall status
Active, not recruiting
Start date
June 18, 2021
Completion date
June 1, 2027
Enrollment
1,500 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cancer